Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

A method of treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, comprising the steps of:

• (a) providing to said patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state a food product that decreases overactive CNS noradrenergic tone;
• wherein said food product that decreases overactive CNS noradrenergic tone comprises:
• 1) protein intake of about 25%±5% of total daily caloric intake;
• 2) monounsaturated fat intake of about 25%±5% of total daily caloric intake;
• 3) saturated fat intake of about 5%±5% of total daily caloric intake;
• 4) polyunsaturated fat intake of about 3%±5% of total daily caloric intake;
• 5) complex carbohydrate intake of about 42%±7% of total daily caloric intake;
• and
• 6) total caloric intake set at 15-25% less than the said patient's daily energy expenditure;
• followed by
• (b) providing to said patient a food product that increases dopaminergic tone while maintaining said decreased overactive CNS noradrenergic tone;
• wherein said food product that increases dopaminergic tone while maintaining said decreased overactive CNS noradrenergic tone comprises:
• 1) protein intake of about 24%±5% of total daily caloric intake;
• 2) monounsaturated fat intake of about 23%±5% of total daily caloric intake;
• 3) saturated fat intake of about 5%±5% of total daily caloric intake;
• 4) polyunsaturated fat intake of about 3%±5% of total daily caloric intake;
• 5) complex carbohydrate intake of about 45%±7% of total daily caloric intake;
• 6) total caloric intake set at 0-25% less than said patient's daily energy expenditure;
• and
• 7) L-DOPA-containing foods in an amount sufficient to ingest about 20-400 mg of L-DOPA per day;
• and
• wherein said polyunsaturated fat intake in each of steps (a) and (b) individually comprise a ratio of omega-3 to omega-6 polyunsaturated fatty acids from between about 0.25:1 to about 2:1;
• and
• wherein said providing step (a) continues for approximately 4 to 12 weeks;
• and wherein said providing step (b) continues for approximately 4 to 6 months.